In the development of antiviral drugs, we can consider designing drugs that target LC3 lipidation, as well as drugs that target molecules associated with the cGAS-STING signaling pathway (such as cGAS, TBK1 and IRF3) to reduce viral replication, thereby improving the efficacy of drug therapy for viral diseases. Here, CGAS is linked to viral load.